|
Daiichi Sankyo is the product of a spurt of merger mania in the Japanese drug business. After Sankyo purchased rival Daiichi Pharmaceutical for more than $7 billion in 2005, the two companies merged their operations into the newly formed Daiichi Sankyo, creating a top pharmaceutical manufacturer in Japan. Daiichi Sankyo manufactures prescription drugs, including treatments for cardiovascular, bone and joint, and infectious diseases. Its products are sold through medical representatives located worldwide. The company also makes over-the-counter (OTC) and generic drugs, as well as veterinary products and assorted chemicals.
|
| | | Contact Information | |
Address: |
3-5-1 Nihombashi-honcho, Chuo-ku
Tokyo 103-8426, Japan
| | Phone: | +81-3-6255-1111 | | Fax: | +81-3-6255-1132 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2008): | 8863.70 M | | Revenue Growth (1 yr): | 12.40% |
|
|
Key People
| | • |
Chairman and Representative Director:
Kiyoshi Morita
| | • |
President, CEO, and Representative Director:
Takashi Shoda
| | • |
Executive Director and Senior Executive Officer Sales and Ma:
Ryuzo Takada
|
|
|
